Pieruzzini et al., 2020 1125

Running title:

Value of Venezuelan Olfactory test in SARS-CoV-2 infection

TYPE OF ARTICLE

ORIGINAL CONTRIBUTION

What do we know about smell and taste dysfunction by SARS-CoV-2. Predictive Value of the Venezuelan Olfactory test and RT-PCR analysis in viral infection diagnosis

Rosalinda Pieruzzini^{*1}, Carlos Ayala-Grosso^{*2}, Jose de Jesus Navas³, Wilneg Rodríguez¹, Nathalia Parra¹, Emily Luque¹, Aida Sánchez-Gago¹, Scarleth González¹, Alexandra Hagobian¹, Angeline Grullón¹, Karen Díaz¹, Mariano Morales¹, Melanie De Jesús¹, Sonia Peña¹, Luis Rodríguez¹, Luis L Peña⁴, Ana Asaro⁵, Magda Magris⁶

1. Department of Otorhinolaryngology. University Military Hospital “Dr. Carlos Arvelo”.
Neurorhinology Unit. San Martín- Caracas-Venezuela

2. Unit of Cellular Therapy, Centre of Experimental Medicine, Instituto Venezolano de Investigaciones Científicas (IVIC). Caracas, Venezuela.

3. Direction of General Health, Fuerzas Armadas Nacional Bolivariana. Caracas-Venezuela.

4. Hospital “Dr. José María Vargas”. Instituto Venezolano de los Seguros Sociales. La Guaira-
Venezuela

5. University Military Hospital “Nelson Sayago Mora”. La Asuncion. Nueva Esparta-Venezuela

6. Ministry of Popular Power for Health. Caracas-Venezuela

SUMMARY

Background: Smell and taste disorders are reported very frequently and at an early stage in the evolution of the infectious disease caused by the SARS-CoV-2. These symptoms could be sensitive and specific to establish the condition of the infection, and may suggest the flow of decisions as to further therapy. We asked whether smell and taste impairment are earlier and more sensitive symptoms than the RT-PCR molecular assays for SARS-CoV-2 detection.

Methodology: Subjects (N=275) with a probable COVID19 diagnosis were classified as follows: Symptomatic with chemosensory dysfunction, symptomatic without chemosensory dysfunction, and asymptomatic. Subjects received a general clinical and otorhinolaryngology examination. Evaluation of the chemosensory dysfunction

was performed by means of the Venezuelan Olfactory Test and taste test. Nasal swabs and blood samples were analyzed by real-time polymerase chain reaction analysis (RT-PCR) and a rapid diagnostic test to detect the SARS-CoV-2 virus and antiviral antibodies, respectively. Patients had access to molecular tests and smell and taste evaluations every 3 to 5 days until they recovered.

Results: Out of 44 patients that were positive for RT-PCR SARS-CoV-2: 45.83% had smell and taste disorders and COVID19 symptoms, 23.61% did not have smell or taste disorders, but had COVID19 symptoms, and 30.55% were asymptomatic. Mild hyposmia and hypogeusia account for the most frequent chemosensory disorders accompanying common SARS-CoV-2 symptoms. Time to recover from the chemosensory dysfunction ranges from 3 to 14 days, up to a maximum of 5 weeks, while RT-PCR becomes negative after 21 days and up to 35 days in some cases. The Venezuelan Olfactory Test and taste test has a 61.68% positive predictive value, 45.83% sensitivity, and 68.7% specificity for SARS-CoV-2 infection.

Conclusions: Smell and taste disorders are frequent symptoms of SARS-CoV-2 infection, but not a significant predictor of the disease, as compared to the molecular RT-PCR test.

Key words: COVID19, Smell, Taste, diagnosis, RT-PCR, olfactory test

INTRODUCTION

At the early stages of the SARS-CoV-2 infection, the smell and taste disorders seem to have some predictive value as to the evolution of the infection (1). Since the beginning of the pandemic, multiple studies have reported a very variable association between the smell and taste dysfunction and the presence of other symptoms that are characteristic of the coronavirus infection (1).

The first reports of a multicenter study that grouped clinical data from 12 hospitals, a population of 417 patients with mild to moderate COVID-19, list cough, myalgia and loss of appetite as the most common symptoms; while symptoms associated with otorhinolaryngology-related disorders were facial pain and nasal obstruction in at least 86% of the cases; and there were smell and taste disorders in 88% of the cases. The onset of the smell dysfunction was earlier than any other symptom in 11.8% of the cases (2).

The sudden loss of the sense of smell associated with an increasing number of cases

72 of coronavirus was reported in the United Kingdom recently; however, the evidence
73 seems to be circumstantial, because it was found as information provided in social
74 media by subjects who had had this symptom in an isolated fashion. The authors
75 reported 9 cases of sudden anosmia without other associated symptoms in the first 3
76 weeks of the onset of the coronavirus. It is worth mentioning that none of these
77 patients was evaluated with a specific test to determine the presence of the disorder
78 (3).

79 More recently, another study carried out at Hospital L. Sacco in Milan, Italy with 59
80 of the 88 patients of the hospital, established that 33.9% had at least one smell and/or
81 taste disorder and 18.6% had both. In this group of patients, 20.3% had smell
82 symptoms before they were admitted to the hospital and 13.5% during their stay (4).

83 The presence of smell alterations associated with a viral infection is not new in
84 otorhinolaryngology; many viruses may cause olfactory dysfunction due to an
85 inflammatory process of the nasal mucosa and the development of rhinorrhea. Among
86 the viral agents associated with these alterations are rhinovirus, parainfluenza,
87 Epstein-Bar, and some coronavirus (4,5). However, the fact that olfactory dysfunction
88 associated with SARS-CoV-2 is not essentially related to the onset of rhinorrhea and
89 nasal obstruction suggests a different action mechanism. So far, the physiopathology
90 of smell and taste disorders in the SARS-CoV-2 infection is still under scrutiny.

91 One of the most relevant evidences of the action mechanism of coronavirus was
92 reported as a result of an investigation of the olfactory mucosa of mice and analysis of
93 RNA sequences of humans. It found that the 2 genes that express the information for
94 angiotensin-converting enzyme 2 (ACE2) and the host transmembrane serine protease
95 family member II (TMPRSS2) receptors involved in the entry of COV-2 into the cell
96 are expressed in the cells of the respiratory epithelium of the nasal cavity, support
97 cells, Bowman's glands, microvilli, and stem cells of the olfactory mucosa, but not in
98 the olfactory sensory neurons. This suggests that the olfactory damage mechanism is
99 non-neural in nature. As to the damage to the sense of taste, it appears to be directly
100 on the taste receptor and as the result of the production of cytokines that irritate the
101 trigeminal and glossopharyngeal nerves that transmit sensory signals to the central
102 nervous system (6).

103 Netland et al. found that, in certain transgenic mice, there was an extensive replication
104 of the virus in the brain, with certain regional differences, and that this brain infection,
105 in turn, was an important factor in the aspiration pneumonia seen in some of the mice

studied. A generalized neuronal infection appeared after intranasal inoculation, which suggests that the entryway for the infection could be through the olfactory bulb. This raises questions about the possible effects of coronavirus on patients infected with SARS-CoV-2 in the future (7).

A vast majority of initial reports on smell and taste dysfunction related to coronavirus infection were based on results from patient surveys, without corroborating the diagnosis through psychophysical evaluation of chemosensory dysfunction. Patients were not followed up systematically until recovery, nor was the relationship proven by means of diagnostic tests, such as the SARS-CoV-2 RT-PCR test, or rapid diagnostic tests. These factors may have led to an overestimation of the symptom as predictive factor of the disease. Similarly, using the smell test without adjusting it to the population under analysis could result in some false positives and, consequently, an overestimation of chemosensory dysfunction diagnostics.

All of the above motivated us to carry out an investigation the distinctive nature and main objective of which was to determine the predictive value of smell and taste tests in the diagnosis of SARS-CoV-2 infection, and its relationship with other diagnostic tests, such as SARS-CoV-2 RT-PCR test and the rapid diagnostic test, as well as the follow up and comprehensive observation of the patient's recovery from the coronavirus infection. The objective of this study is to determine whether smell and taste disorders are an early and more sensitive biomarker than the RT-PCR test for diagnosing the SARS-CoV-2infection.

MATERIALS AND METHODS

Population

A sample of 275 individuals was selected from a population of 525 subjects examined between March and August 2020 (Table 1). The following were collected for all subjects at the beginning of the study protocol: 1. Full clinical record, including age, gender, epidemiologic background on the basis of travel and contact with positive cases, questions about suggestive respiratory signs and other symptoms, presence or not of smell and/or taste disorders. 2. General otorhinolaryngology (ORL) physical examination, Venezuelan Olfactory Test (VOT), and Basic Taste Test evaluation . 3. Nasopharyngeal swab for SARS-CoV-2 by RT-PCR molecular analysis and detection of SARS-CoV-2 antibodies by rapid diagnostic test (RDT).

In this study, patients were followed-up every 3 to 5 days, to verify their overall clinical condition. In addition, smell and taste tests were carried out, blood samples

were drawn to perform RDTs, and nasopharyngeal swabs for RT-PCR tests, until they met the recovery criterion. The recovery criterion is met when one of the following conditions is fulfilled: 1.-The relative smell and taste test score is at the highest level and the RT-PCR test is negative. 2. - It has been established that there is no permanent smell or taste disorder.

Clinical assessment

The clinical assessment of patients with probable COVID19 diagnostic followed the guideline suggested by the National Institute of Health of the United States of America (NIH-USA SARS-CoV-2 assessment guidelines). The level of organ compromise is defined as **mild or moderate** if individuals present with fever, cough, sore throat, general malaise, headache, myalgia, anosmia, ageusia, and diarrhea. When it is a **mild** condition, patients do not complain of shortness of breath, have more than 94% oxygen saturation, and there is no clinical evidence of respiratory disease, while in the **Moderate** there is clinical and imaging evidence of mild respiratory disease. The condition is defined as **Severe** in individuals with less than 94% oxygen saturation and respiratory rate at 30 respirations per minute in adults, in addition to more than 50% pulmonary infiltrates or a PaO₂/FIO₂ ratio lower than 300 mmHg. In the case of **Critical** disease, there is respiratory distress which requires mechanic ventilation, as well as multiple organ failure, septic shock and vasopressor treatment.

Venezuelan Olfactory Test (VOT) and Taste Test

The VOT is a smell test that was adapted for Venezuela from the smell identification test of the University of Pennsylvania (UPSIT) (8). The Venezuelan short test is composed of 2 notebooks with 10 odorants that are commonly recognized by Venezuelans and which were validated during a prior exploratory study (9, 10). The substances are coffee, chocolate, baby cologne, scented talc, liquid detergent, coconut essence, powdered detergent, cinnamon, acetone, and rum. Every time an odorant is examined, the subject must identify the respective smell and discriminate it among the other substances offered and mentioned in addition to the odorant he is expected to identify.

On the basis of identification and discrimination of odors presented to patients, the VOT provides a relative grading scale as follows: Normosmia (8-10), mild hyposmia (6-7), moderate hyposmia (5-4), severe hyposmia (2-3), and anosmia (0-1).

The taste test consists in recognizing the 5 universally accepted basic tastes, to wit:

sweet, salty, sour, bitter, and umami (11). One (1) cc of a sample of each taste is placed on the anterior third of the tongue of the patient who has his eyes closed, and after 10 seconds of period, an identification of the sample may occur. If the patient cannot recognize the tastes, he is diagnosed with ageusia, and hypogeusia if the patient recognized up to 4 tastes.

Rapid Diagnostic Test (RDT) to Determine Antibodies Generated to SARS-COV-2 virus antigens

Diagnostic tests N° IFU-COVID3-01 (Nhui deep blue Medical Technology co. Batch: 20200307) were used to determine IgG/IgM antibodies. This kit uses a recombinant SARS-CoV-2 antigen conjugated with colloidal gold, which can interact with antibodies circulating in blood or in a serum or plasma preparation. The sample is placed on a nitrocellulose (NC) membrane that has been prepared with rat anti-IgM antibodies and human IgG antibodies, and sheep anti-rat polyclonal antibodies. When the sample diffuses in the membrane it may interact with the IgM antibodies adsorbed in it and an aggregate is produced with the coronavirus antigen marked with colloidal gold. This, in turn, is captured by the rat anti-IgM and produces a colored line. If the sample contains IgG antibodies, it forms a compound with the antigen marked with colloidal gold, this compound is captured by the rat anti-human IgG antibody and produces a colored line. When samples contain IgM and IgG at the same time, there will be 2 lines. When there are no IgM or IgG antibodies in the sample, there is only the quality control line and the result is negative.

Sample Collection for RT-PCR Testing for SARS-CoV-2 detection

Samples were obtained from patients by nasopharyngeal swab strictly following the biosecurity protocol. Then, they were placed in YOCON viral transport medium, batch Y25200101, and kept at a temperature between 2 and 8°C until they reached the reference laboratory. Samples collected for RT-PCR testing for SARS-CoV-2 detection were processed by the Virology Service of the “Rafael Rangel” National Hygiene Institute of the Ministry of the People’s Power for Health in Caracas, Venezuela.

Ethical Approval

Collection and analysis of data were approved by the Bioethical committee of the “Carlos Arvelo” University Military Hospital of Caracas. All studies were conducted in compliance with the Declaration of Helsinki, and all participants signed an informed consent. The current study included participants for which there was full

information on multiple SARS-CoV-2 measures and key outcomes, including psychosocial factors, chronic medical conditions, and socio-demographic factors.

Statistical Analysis

Descriptive statistics was used in the analysis by age group and type of chemosensory impairment. The predictive value, sensitivity and specificity of diagnostic tests used were calculated on the basis of the Wilson score method using the OpenEpi, version 3 software. Diagnostic Test Open code Calculator.

χ^2 -Square tests were used to find the most frequent type of symptom in the SARS-CoV-2 infection. We asked whether there is a relationship between the SARS-CoV-2 infection and the presence or absence of symptoms; and to evaluate the relationship among type of olfactory disorder, age and gender. In the case of the association between two variables, when the result of the χ^2 -Square test was positive, that is to say, the variables were dependent on, or associated to one another, a standardized residuals analysis was carried out. This analysis allows to determine in a significant manner which cell or frequency contributed more to the rejection of the null hypothesis in the χ^2 -Square test. Additionally, it allows to find out which cells deviated significantly from the expected value. Any deviation value higher than ± 1.96 from the normal distribution is considered significant.

Pearson's χ^2 -Square test and Fisher's exact test were used to evaluate between-group differences in two categorical variables.

χ^2 -Square tests and standardized residuals analyses were carried out in R with the chisq.test function of the stats. package (12).

RESULTS

The most frequent age group among study subjects was the 25 - 38 years old, and there were more male (54.90 %) than female (45.09 %) subjects; average age of the population was 33.63 ± 5 years old (Table 2). In Venezuela, the first possible SARS-CoV-2 infection cases were reported in March (Figure 1). Initially, the disease was observed in a group of 28 patients with smell and taste disorders, although only 1 of them was confirmed positive for SARS-CoV-2 by means of the RT-PCR test. Then, starting in May, the number of individuals positive for SARS-CoV-2 was increasing in parallel with the onset of smell and taste disorders; and finally, in the month of August, a significant number of patients with smell and taste disorders also tested positive for coronavirus infection by means of the RT-PCR test.

The observation of a higher incidence of olfactory and taste disorders together with a

242 positive molecular diagnostic suggested that the dysfunction of these senses could
243 happen before or to a greater extent than the expression of viral genes evidenced by
244 the RT-PCR test, and this could imply that the physiology of the chemosensory
245 system is more susceptible to SARS-CoV-2 infection.

246 To assess this observation, molecular tests were performed on the 275 subjects who
247 had gotten smell and taste tests. It was found that 144 subjects were RT-PCR+ for
248 SARS-CoV-2 while 131 were RT-PCR- for SARS-CoV-2. In the RT-PCR+ group,
249 there were more SyMVOTT+ (66/144; 45.83%) subjects than SyMVOTT- (34/144;
250 23.61%) or ASYM (44/144; 30.55%). In contrast, among the 131 patients that tested
251 negative for SARS-CoV-2 in the RT-PCR test, there were more SyMVOTT+ (41/131;
252 31.30%) subjects than SyMVOTT- (27/131; 20.61%), but less than the ASYM
253 (63/131; 48.10%) (Table 3). These results suggest that there are more individuals with
254 olfactory and taste disorders among the COVID19 symptomatic population.

255 The higher number of RT-PCR+ patients with and without olfactory and taste
256 disorders, and with symptoms of the infection indicates that the relative effectiveness
257 of RT-PCR tests in confirming the COVID19 infection is 75%. In contrast, if the large
258 number of PDR- (197/275; 71.63%) individuals in the whole sample is taken into
259 account, the relative effectiveness of this test is 28%. (Table 3). This confirms the
260 little reliability of PDR tests for diagnosing coronavirus infection.

261 The frequency of subjects in the SyMVOTT+, SyMVOTT- and ASYM groups as a
262 function of the presence of chemosensory symptoms and the positive molecular test
263 results was heterogeneous ($X^2 = 9.19$, $gl = 2$, $p < 0.05$), which suggests that the type
264 of symptoms and their association with chemosensory dysfunction is different in the
265 case of SARS-CoV-2 infection. This is consistent with what was observed in the
266 analysis of standardized residuals, since, in the SARS-CoV-2 infection, the
267 chemosensory dysfunction is very frequent and, in this sample, very few subjects that
268 presented with the disease were asymptomatic (Table 4.1, Figure 1). On the other
269 hand, olfactory and taste disorders are infrequent in the general population (Tables 3
270 and 3.1).

271 Predictive Value of VOTT

272 When the frequency of patients with olfactory and taste disorders that were diagnosed
273 with the VOTT was compared to the RT-PCR tests positive results, the positive
274 predictive value of the VOTT was 61.68%, while the negative predictive value was
275 53.57%. These results suggested that VOTT+ patients had a 0.62 probability of being

276 RT-PCR+ for SARS-CoV-2. On the other hand, the sensitivity and specificity for
277 COVID-19 diagnosis of the Venezuelan Olfactory Test and basic taste test was
278 45.83% and 68.7%, respectively (Table 4). These findings supported that these tests
279 allow to detect olfactory and taste disorders in 46% of healthy individuals and in 69%
280 of patients who were also clinically SARS-CoV-2 positive.

281 *SARS-CoV-2 Affection and Chemosensory dysfunction*

282 Coronavirus infection produces different degrees of affection, as described in the
283 methods. In this research, it was observed that 98.48 % of the 66 subjects (65/66) with
284 chemosensory impairment (VOTT+) had mild clinical signs and 1.51% (1/66)
285 moderate signs (Table 5).

286 *Characteristics of VOTT+, SyVOTT+, and SyVOTT- Patients*

287 Clinical signs as a consequence of SARS-CoV-2 infection are quite variable. The
288 number of SARS-CoV-2 infected patients presenting with chemosensory disorder
289 only (VOTT+) was 18/97 (18.55%). In contrast, there were 48/97 (49.5%) SyVOTT+
290 according to standardized residuals analysis $P < 0.05$; (Table 6).

291 The group of VOTT+ patients without any other accompanying symptom (no
292 concomitants), who referred olfactory and taste disorder as their only symptom before
293 the molecular diagnostic and before being admitted to the hospital was 18/97
294 (18.55%) (Table 7). When differentiated on the basis of the type of chemosensory
295 dysfunction, 7 presented with olfactory disorder only, 4 of them anosmia, and 3 with
296 mild hyposmia. Combined smell and taste disorders at various degrees were present in
297 10 subjects, and only 1 had hypogeusia. All these findings suggest a disorder
298 variability that may indicate the presence of coronavirus infection and not only the
299 anosmia or the ageusia. In this group of patients, chemosensory disorders were an
300 early biomarker of the coronavirus disease.

301 Chemosensory dysfunction was a symptom in 31.25% of the subjects of the
302 SyVOTT+ group before being admitted to the hospital. In contrast, 68.75% of the
303 patients of the sample that did not declare the disorder before being admitted to the
304 hospital, were positive for olfactory or taste disorder when the VOT and taste test
305 were used. This confirms the need to use a standardized objective taste for detecting
306 the chemosensory disorder during the hospital stay. On the other hand, the onset of
307 the chemosensory dysfunction in the SyVOTT+ group occurred between the 3rd and
308 5th day in 70% of the cases.

Other associated symptoms in the SyVOTT+ group vary. Among them, headache, myalgia, arthralgia, shivering, odynophagia, and hyporexia in 48% of patients; fever, headache, and general malaise in 31%, dry cough and chest pain in 8% dyspnea, and only fever or myalgia in 8% and 2%, respectively.

Similarly, in the SyVOTT- patients, which accounted for 32.98% of the sample, there was fever, headache, myalgia, arthralgia, and shivering in 46.87% of them; headache, arthralgia and myalgia in 15%, as well as chest pain, dyspnea in 15%, rhinorrhea, fever, nasal congestion, and dysphonia in 12.5%; and cough, general malaise, fever, and shivering in 9%. As relates the variety of symptoms in SyVOTT+ and SyVOTT- groups, no differences were observed in the frequency of presentation that would warrant an additional classification in the SARS-CoV-2 infection.

Age, Gender and VOTT

In this study, when the presence of chemosensory dysfunction in the subjects of the sample was taken into account, the frequency was similar among them regardless gender or age (Table 7). Furthermore, smell and taste disorders combined were present in 40.90% of VOTT+ patients. The severity of the disorder is anosmia and ageusia in 30% of the cases, while mild hyposmia and hypogeusia were observed in 59.25% of the cases. The olfactory disorder alone, was present as anosmia (12.12%), severe hyposmia 6.06%, mild hyposmia 25.75%, and moderate hyposmia (6.06%). It may be concluded from the analysis of the sample that the presence of both disorders is the prevailing clinical sign, and of those two, the most frequent olfactory disorder is mild hyposmia (32 patients). At the same time, anosmia was the second olfactory disorder in terms of frequency (17 patients). In contrast, hypogeusia as the only clinical sign is not frequent in coronavirus infection.

Time Course of SARS-CoV-2 Grading by Means of VOT

The assessment of chemosensory dysfunction as a function of time by means of the Venezuela olfactory test allowed to establish a group of subjects with anosmia 11/31 (35.48%) and another with mild hyposmia 15/31 (48.4%) on day 1. The number of individuals positive for mild hyposmia and normosmia in the VOT increased in frequency with time, as follows: day 5, 8/10 (80%); day 7, 17/19 (89.5%); day 10, 8/8 (100%); day 14 8/10 (80%); and day 20, 15/16 (93.75%). Between day 5 and day 20, the sense of smell of 66/142 (46.47%) subjects had been restored (normosmia), as evidenced by the VOT test. The average recovery interval was 8 to 10 days, with a

minimum of 3 days and a maximum of 20 (Figures 2A and 2B). Only one patient did not recover the sense of smell during the time of the study.

Time Course of SARS-CoV-2 Grading by Means of RT-PCR Test

The frequency analysis of the RT-PCR molecular test for SARS-CoV-2 was carried out for all individuals of the protocol in a systematic manner from day 1 to day 34 post infection. The viral gene expression was very frequent from day 1 to day 7, as it was present in 47/78 (60.25%) subjects; it decreased between day 10 and 14, and from day 16 to day 20, when it was evident in 15/78 (19.23%) and 11/78 (14.10%) subjects, respectively. Only 3 individuals had a positive RT-PCR test result on day 26 and only one did so until day 30. The frequency of VOTT+RT-PCR+ 66/275, and VOTT-RT-PCR+ 78/275 individuals is different from that of VOTT+RT-PCR- 41/275, VOTT-RT-PCR- 90/275 subjects (Fisher's exact test $P < 0.0184$). The frequency of RT-PCR+ molecular tests is higher between days 1 and 14 and lower between day 16 and 24. It was observed that the maximum time interval for viral gene expression was 21 days (Figure 3).

DISCUSSION

The recent onset of this SARS-CoV-2 zoonosis in human populations has led to a significant number of studies aimed at understanding the variety of symptoms as part of the etiology of the disease. In the Venezuelan population, the time course of COVID19 has been lagging behind that of other countries, and this may have given time to establish treatment guidelines as a function of the expression of the disease.

This study have evaluated the predictive value of a standardized smell test for the unbiased assessment of the sense of smell and taste in individuals with respect to a molecular diagnostic of SARS-CoV-2 infection by RT-PCR test. This is an original and innovative study, as it establishes in an objective and recurrent evaluation, by means of a smell test that is standardized for Venezuela and a classical taste test, the evolution of the chemosensory disorder of subjects until the sense of smell and taste are fully restored. Additionally, the viral genes analysis by means of the SARS-CoV-2 RT-PCR test and of the anti-coronavirus antibodies was carried out in symptomatic and asymptomatic patients until these had fully recovered.

Clinical signs vary in patients with coronavirus infection, and the severity of the disease is determined by shortness of breath, oxygen saturation, pulmonary infiltrates, multiple organ failure, septic shock, and the need to use vasopressors, as defined by the National Institute of Health of the United States of America (NIH-USA SARS-

376 CoV-2 assessment guidelines).

377 Anosmia and ageusia were otorhinolaryngological and neurological signs of the

378 coronavirus disease. Currently, the physiopathology of anosmia due to COVID-19 is

379 apparently better understood; however, there is still the question why patients with

380 moderate to severe COVID-19 infection have less olfactory affectation. Findings of

381 this study show that 98% of patients with smell and taste disorders had mild

382 COVID19. These results are in agreement with a recent report of self-described

383 olfactory dysfunction in mild forms of SARS-CoV-2 infection that did not require

384 hospitalization (13). For instance, the chemosensory dysfunction established in this

385 study by means of self-evaluation underestimates the incidence of this symptom;

386 therefore it would be advisable to examine whether anosmia is less prevalent in more

387 severe forms of the infection and, consequently, the mechanism that leads to the

388 physiopathological process that gives rise to this affectation.

389 The definition of a mild or severe form of SARS-CoV-2 infection may imply there is

390 an immune response with more or less contention power thus leading to a milder or

391 more serious viral infection, respectively. This response in the entryway of the virus

392 may also imply that the progression of the infection depends on the time taken by the

393 virus to move towards the upper or lower airways. Therefore, it is possible that, in the

394 mild forms of the coronavirus infection, a more intense and faster immune response

395 will produce more local inflammation that evolves into inflammatory processes

396 involving the neuroepithelium and olfactory bulb. In contrast, in low intensity late

397 immune responses, patients present with mild symptoms in ears, nose and throat; but

398 later, these could also involve higher and lower airways with respiratory compromise

399 (14, 15).

400 These two hypotheses have not been experimentally corroborated, because results

401 show that patients with severe or critical forms have a higher immunoglobulin

402 concentration in the serum and nasal secretions than patients with mild forms; which

403 additionally makes sense, because the severe respiratory compromise has been

404 justified as being a cytokine storm mechanism.

405 Since the beginning of the pandemic, COVID-19 symptoms reports have been about

406 the respiratory tract affectation, with serious and fatal complications in a certain

407 percentage of cases. The first reports involving a nervous system affectation were

408 associated to a sudden decrease in the sense of smell, sometimes accompanied by a

409 decrease in the sense of taste, which patients recovered from regardless whether they

410 had a positive infection outcome or not. Initial reports were based on telephone
411 interviews or online self-assessments by means of a questionnaire. As a result, the
412 incidence of the chemosensory disorder was 19.4% (2); 64% (16); and 85.6% (15).
413 These findings confirmed the initial observation of Lechien et al. who were the first to
414 mention the sudden loss of the sense of smell in SARS-CoV-2 infected patients.
415 Subsequent reports expanded on the vision of this author and confirmed the
416 association between the infection by this virus and the chemosensory disorder. Self-
417 assessment of the senses of smell and taste has been proposed as an index of SARS-
418 CoV-2 transmission that could be of value for projecting the need of hospital care
419 units required for compromised patients (17). However, as it is commonly the case in
420 these smell and taste self-assessment studies, sensitivity and specificity are
421 compromised.

422 Applying standardized tests to SARS-CoV-2 infected patients has allowed to
423 determine the level of involvement of the sensory function in the progression of the
424 viral pathology. In a previous study, an UPSIT test for the Persian population applied
425 to a reduced number of patients in Iran established that the olfactory disorder is
426 variable, as there was a reduced rate of anosmic subjects (25%), while the largest
427 percentage had moderate and severe microsmia (60%). Therefore, it was suggested
428 that this degree of sensitivity was not enough to be able to consider the smell test as
429 an indicator of the progression of the infection (18).

430 The senses of smell and taste form a physiological system that is affected by COVID-
431 19; however, the degree of affectation seems to be mild. This has been shown by the
432 studies carried out using as objective evaluator the chemosensory test of the Clinical
433 Research Center of Connecticut, which has shown, just like Moein et al., findings,
434 that a very small number were anosmic, while most had moderate and mild hyposmia
435 (80%). At the same time, the taste test established that the taste affectation was mild
436 to moderate. All patients maintained a normal degree of discrimination and a
437 subjective overall recovery of 66%; but up to 88% presented with a certain degree of
438 chemosensory disorder (19).

439 In contrast with these results, in this study, the results of several smell and taste tests
440 showed the progressiveness of the disorder and time to recover from the onset of the
441 infection. Contrary to what was seen in prior studies, in our sample, mild hyposmia
442 and anosmia accounted for the highest share with a progressive recovery. The onset of
443 the infection and its evolution allowed to make an evaluation until the recovery of the

444 patient.

445 Evidence of SARS-CoV-2 infection and its demonstration by virtue of new

446 technologies have given rise to molecular tests with variable sensitivity and

447 specificity. Findings suggesting an asymptomatic infection in significantly frequent

448 cases of negative RT-PCR test results imply several possibilities, which include that

449 individuals have either not been exposed to the infection or they received a reduced

450 viral load. At the same time, the characteristics of the sample, as a result of collection,

451 storage, preservation, and processing, could also contribute to the high number of

452 negative results (20,21).

453 The time course of the infection, and the effectiveness of molecular tests to prove the

454 infection, suggest an order in the events of infection progression that range from 5 to

455 7 days for the first clinical signs to become evident. The sensitivity of the molecular

456 diagnosis increases in a delayed manner, as a function of the increase in the

457 concentration of viral particles that could reach a maximum level on the 7th day and

458 up to the following 14 days, to then decrease gradually as a result of the immune

459 response of the patient.

460 In contrast, in this study, the RT-PCR molecular test leads to suggest a minimum time

461 of 1 day from the date of admission of the patient to the protocol and up to 14 days.

462 This is the first study that established a multiple system for following up the

463 progression of the chemosensory disorder and detecting the infection; be it by means

464 of the molecular test or the SARS-CoV-2-specific antibodies detection test. The

465 Venezuelan olfactory test is a tool that has been validated taking into consideration

466 the characteristics of the Venezuelan population.

467 In this research, we corroborate the spontaneous recovery of most patients. Only one

468 patient still has anosmia-type smell disorder; and in her case, other tests were carried

469 out to establish the actual cause of such disorder. In this regard, there is similarity

470 with what has been reported in the literature about recovery time. We did not find in

471 our review of other investigations any relationship between the persistence of

472 chemosensory dysfunction and the negativization of the RT-PCR test. Apparently,

473 there is no relationship between the improvement of the disorder and the viral load

474 detected by molecular and/or serologic tests.

475 The presence of asymptomatic SARS-CoV-2 positive patients and the fact that the

476 predictive value of the Venezuelan olfactory test and the basic taste test does not

477 exceed 70% may be hypothetically explained, not only by the time when the

investigation began - which was too early with respect to the contagion peak in the country- but also by some social, demographic, and genetic characteristics of the sample studied. It could also be due to the virus mutations that affect certain populations.

In this regard, the SARS-CoV-2 spike mutation has been described as mediating the infection in human cells. Korber et al. listed 13 mutations that are deemed to be within a wider phylogenetic spectrum that could change with geography and with time, and which could give some populations certain selective advantages as to the transmission or resistance to the infection. In the case of Europe, the spike mutation D614G was dominant and began spreading in February 2020 and had such aggressive impact on the population. There is evidence of recombinant strains circulating locally and that are indicative of infections by multiple strains (22). This is being researched currently in Colombia and Venezuela. Rodríguez-Morales et al. (23) described 3 genomic sequences of coronavirus mutations that may explain the behavior of the disease in Venezuela, in specific zones like Zulia, (where there has been significant migratory activity of people to and from Colombia and Brazil) and where the severity of the infection has been higher than in other geographic zones of the country (23). This hypothesis could explain why infections are mild or asymptomatic in some areas and severe in others, or why the penetrance of chemosensory dysfunction is lower than in other reports.

We may conclude that there is significant presence of smell and taste disorders, as clinical signs, in the course of the mild coronavirus disease. Therefore, every patient who presents with symptoms, must be isolated and screened for the disease by means of appropriate diagnostic tests. Patients evolve towards the resolution of smell and taste disorders spontaneously and recover in a period of time between 3 days and 5 weeks, with an average of 8 to 10 days. Rapid diagnostic tests are not useful for diagnosing the coronavirus infection, but only for following it up. We would suggest including the olfactory test and taste test as part of the battery of tests complementary to the RT-PCR test for diagnosing SARS-CoV-2 and following up the progression of the disease.

ACKNOWLEDGEMENTS

Authors acknowledge to Physicians José M. García, Francis Sánchez, Isabel Duque, David Forero, Ptte Margaret Tovar, and Ptte María Barico. Altogether contributed supporting organization, and care of patients. Special mention goes to following

health Centres: Hospital Militar Universitario “Dr. Carlos Arvelo” (San Martín-
Caracas), Hospital “Dr. José Ignacio Baldó” (Algodonal-Caracas), Hospital General
“Dr. Jesús Yerena” (Lídice-Caracas), Hospital Oftalmológico “Dr. Francisco
Risque” (Cotiza- Caracas), Hospital de los Seguros Sociales “Dr. Miguel Pérez
Carreño” (Caracas), Hospital de los Seguros Sociales “Dr. José María Vargas” (La
Guaira), Hospital Militar “Nelson Sayago Mora” (La Asunción-Nueva Esparta),
Hospital Militar “ Dr. Vicente Salias” (Fuerte Tiuna-Caracas), Policlínica
Metropolitana (Estado Miranda), Hospital Clínico Universitario de Caracas.

Other case screening centers of the Health Department of the national Armed Forces
located in the Great Metropolitan Area of Caracas:
General Command of the Army and Aviation, ‘Seguros Horizonte’ headquarters,
Military Prosecution Department, TVFANB headquarters, National Armed Forces
Bank head office.

525

526 AUTHORSHIP CONTRIBUTION

527 R. Pieruzzini, M Magris and C Ayala-Grosso, designed and performed the research.
528 R. Pieruzzini, JJ Navas, W Rodríguez, N Parra, E Luque, A Sánchez-Gago, S
529 González, A Hagobian, A Grullón, K Díaz, M Morales, M De Jesús, S Peña, L
530 Rodríguez, LL Peña, A Asaro, M Magris, performed research, C Ayala-Grosso, A
531 Hagobian, M Magris, R Pieruzzini performed research and analyzed data; R.
532 Pieruzzini, and C Ayala-Grosso revised, analyzed, and wrote the manuscript. **R.**
533 **Pieruzzini and C Ayala-Grosso** equally contributed in analyzing data and wrote the
534 manuscript.

535 CONFLICT OF INTEREST

536 The authors of this investigation have no conflicts of interest to declare

537 FUNDING

538 Resources for rapid tests and the viro cult, as well as other supplies for sample
539 collection and processing, were provided by the Ministry of the People’s Power for
540 Health of Venezuela.

541 The disposable olfactory test kits were home-made and self-funded by the developers
542 of the VOT as follows: Wilneg Rodriguez, Carlos Velasquez and Rosalinda
543 Pieruzzini.

544

REFERENCES

1. Lechien JR, Chiesa-Estomba CM, De Siati DR et al.. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngology* 2020; 277(8):2251-2261.
2. Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? *Rhinology* 2020;58(3):299-301.
3. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. *Lancet Respir Med* 2020;8(5):518-526.
4. Giacomelli A, Pagani G, Ridolfo AL, et al. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. *J Med Virol* 2020; 10:10.1002/jmv.26407.
5. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. *J Chin Med Assoc* 2020;83(3):217-220.
6. Brann DH, Tsukahara T, Weinreb C, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. *Sci Adv* 2020;6(31):eabc5801.
7. Netland J, Meyerholz DK, Moore S, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. *J Virol* 2008;82(15):7264-75.
8. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. *Laryngoscope* 1984;94(2 Pt 1):176-8.
9. Pieruzzini R, Rodríguez W, Velazquez C. Short Adaptation of the smell test of the University of Pennsylvania (UPSIT) for the Venezuelan population. medRxiv: <https://medrxiv.org/cgi/content/short/2020.08.25.20182063v1>
10. Hagobian A, Pieruzzini R. Test del Olfato Hospimil vs Test de Connecticut para Diagnóstico de trastornos olfatorios. *Acta Otorrinolaringológica* 2020; 31(2):14-20.
11. Castro L, Pieruzzini R, Luque E, Garcia L. Propuesta de un Test del gusto para la población Venezolana. *Acta Otorrinolaringológica* 2020; 31 (1) :17-26.

- 579 12. Agresti, A. (2007). *An Introduction to Categorical Data Analysis*, 2nd ed. New
580 York: John Wiley & Sons.
- 581 13. Yan CH, Faraji F, Prajapati DP, et al. Association of chemosensory dysfunction
582 and COVID-19 in patients presenting with influenza-like symptoms. *Int Forum*
583 *Allergy Rhinol.* 2020; 10(7):806-813.
- 584 14. Saussez S, Lechien JR, Hopkins C. Anosmia: an evolution of our understanding
585 of its importance in COVID-19 and what questions remain to be answered. *Eur*
586 *Arch Otorhinolaryngol.* 2020; 9:1–5.
- 587 15. Lechien JR, Chiesa-Estomba CM, De Siaty DR, et al. Olfactory and gustatory
588 dysfunctions as a clinical presentation of mild-to-moderate forms of the
589 coronavirus disease (COVID-19): a multicenter European study. *Eur Arch*
590 *Otorhinolaryngol.* 2020; 277(8):2251-2261.
- 591 16. Spinato G, Fabbris C, Polesel J, et al. Alterations in Smell or Taste in Mildly
592 Symptomatic Outpatients With SARS-CoV-2 Infection. *JAMA.* 2020;
593 323(20):2089-2090.
- 594 17. Pierron D, Pereda-Loth V, Mantel M, et al. Smell and taste changes are early
595 indicators of the COVID-19 pandemic and political decision effectiveness. *Nat*
596 *Commun.* 2020;11(1):5152.
- 597 18. Moein ST, Hashemian SM, Mansourafshar B, et al. Smell dysfunction: a
598 biomarker for COVID-19. *Int Forum Allergy Rhinol.* 2020; 10(8):944-950.
- 599 19. Vaira LA, Deiana G, Fois AG, et al. Objective evaluation of anosmia and ageusia
600 in COVID-19 patients: Single-center experience on 72 cases. *Head Neck.* 2020;
601 42(6):1252-1258.
- 602 20. Kubina R, Dziedzic A. Molecular and Serological Tests for COVID-19 a
603 Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care
604 Diagnostics. *Diagnostics (Basel).* 2020; 10(6):434
- 605 21. Li Z, Yi Y, Luo X, Xiong N, et al. Development and clinical application of a
606 rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J*
607 *Med Virol.* 2020; 10.1002/jmv.25727.
- 608 22. Korber B, Fischer WM, Gnanakaran S, et al. COVID-19 Genomics Group,
609 McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC,
610 Saphire EO, Montefiori DC. Tracking Changes in SARS-CoV-2 Spike: Evidence
611 that D614G Increases Infectivity of the COVID-19 Virus. *Cell.* 2020; 182(4):812-
612 827.e19.

Pieruzzini et al., 20201125

23. Rodriguez-Morales AJ, Balbin-Ramon GJ, Rabaan AA, et al. Genomic Epidemiology and its importance in the study of the COVID-19 pandemic. Infez Med. 2020; 28(2):139-142.

CORRESPONDING AUTHOR

Rosalinda Pieruzzini MD

Department of otorhinolaryngology.

Unit of Neurorhinology

University Military Hospital “Dr. Carlos Arvelo”.

San Martín- Caracas-Venezuela

rosalindapieruzzini@gmail.com

+58 424 1367083

Table 1. SARS-CoV-2 Group Definition		
Symptomatic with smell and taste dysfunction by VOT (SyMVOTT+)	Symptomatic without smell and taste dysfunction by VOT (SyMVOTT-)	Asymptomatic (ASyM)
N=107	N= 61	N=107
Subjects with general symptoms as described below: headache, cough, fever, general malaise, chest pain, dyspnea, myalgia, arthralgia, shivering, hyporexia, nausea, vomiting, diarrhea and any other symptom described in the literature that might be present and/or suggest a SARS-CoV-2 infection and positive smell and taste results according to the VOT* rating and positive smell and taste results in the VOT grading	Subjects with general symptoms as described below: headache, cough, fever, general malaise, chest pain, dyspnea, myalgia, arthralgia, shivering, hyporexia, nausea, vomiting, diarrhea and any other symptom described in the literature that might be present and/or suggest a SARS-CoV-2 infection	Patients who did not present with any prior symptoms or signs associated with the coronavirus.
VOT: Venezuelan Olfactory Test		

Table 2. Distribution by Age and Gender				
	Males		Females	
	151		124	
Age Range	N	%	N	%
18-24	27	9.81	16	5.81

Pieruzzini et al., 20201125

25-31	41	14.90	32	11.63
32-38	31	11.27	28	10.18
39-45	15	5.45	19	6.90
46-52	16	5.81	9	3.27
53-59	17	6.18	10	3.63
60-66	4	1.45	10	3.63

631

632

Table 3. PCR and PDR Testing								
	PCR+ /PDR+	PCR+ /PDR-	PCR+		PCR- /PDR-	PCR- /PDR+	PCR-	
	N=144			%	N=131			%
SyVOTT+	16	50	66	45.83	38	3	41	31.30
SyVOTT-	14	20	34	23.61	24	3	27	20.61
ASyM	17	27	44	30.55	38	25	63	48.10
$\chi^2=9.19$, gl = 2, p < 0.05								

633

Tabla 3.1 Standardized Residuals for Presence or Absence of Symptoms and SARS-CoV-2 Infection		
Presence of Symptoms	PCR+	PCR-
SyVOTT+	2.56*	-2.56*
SyVOTT-	0.37	-0.37
ASYM	-2.88*	2.88*
*p < 0.05		

634

635

Table 4. Predictive Value of VOT and PCR for Diagnosing SARS-CoV-2 Infection		
	RT-PCR+	RT-PCR-
	N= 144	N= 131
SyVOTT+	66	41
ASyM + SyVOTT-	78	90
χ^2 13.796, gl = 2, P < 0.05		

636

Table 5. Association between Clinical Grading of SARS-CoV-2 Disease and a Positive Venezuelan Olfactory Test and Taste Test (VOTT+)	
Clinical Grading of COVID-19 Disease	VOTT+ (N= 66)
Mild	65 (98.48%)
Moderate	1 (1.51%)
Severe	0
Critical	0

Pieruzzini et al., 20201125

Table 6. General Symptoms and Chemosensory Dysfunction in SARS-CoV-2 Infection

	RT-PCR+		Standardized Residuals
	N= 97	%	
VOT+	18	18.6	-3.14*
SyVOTT+	48	43.9	-3.28*
SyVOTT-	32	37.8	-0.14

X²=13.796, gl = 2, p < 0.01. Chi Square Test X²=13.796, gl = 2, p< = 0.01. * Standardized Residuals significant values p< 0.05. It is worth mentioning that the analysis shown in this table was carried out with all the patients that had symptoms associated with COVID-19 (97/144 positive cases) excluding asymptomatic cases (44/144).

Table 7. VOT+ and taste + by Age and Gender

	Males			Females		
	Age Range (years old)			Age Range (years old)		
	18-35	36-51	>52	18-35	36-51	>52
VOTT*	%			%		
Anosmic	0	3.0	1.5	1.5	3.0	3.0
Mild Hyposmia	7.6	1.5	1.5	7.6	6.1	1.5
Moderate Hyposmia	3.0	0	0	1.5	0	1.5
Severe Hyposmia	1.5	0	0	1.5	3.0	0
Hypogeusia	6.5	0	1.5	1.5	0	0
Both	7.6	6.0	4.5	13.6	3.0	6.1

VOTT* : Venezuelan Olfactory Test and Taste Grading

Legends

Figure 1. Time course of number of cases RT-PCR+ and RT-PCR- along months of COVID19.

The broken line represents the patients with smell and taste disorders who were positive for COVID-19 by PCR-RT. An increase is observed since May with a maximum in July-August. The solid line represents patients with chemosensory disorders without being positive for COVID-19.

Figure 2. Olfactory impairment and evolution of SARS-CoV-2 infection. Venezuelan

Pieruzzini et al., 20201125

651 Olfactory Test was performed until Olfactory Index Grading reached normosmic
652 value (8-10). A. Each bar represents number of subjects at specific grade of olfaction.
653 Bar symbol represents day of testing (Day 1 -10). B. Each bar represents number of
654 subjects at specific grade of olfaction. Bar symbol represents day of testing (Day 12 -
655 20)

656

657 Figure 3. Evolution of RT-PCR molecular analysis under SARS-CoV-2 infection.
658 RT-PCR molecular analysis was performed multiple times to each patient until
659 testing become negative. Each bar represent the number of patients RT-PCR+
660 (black) and RT-PCR- (white) through time (days of PCR testing).

661

662

Figure 1

Figure 2

Figure 3A

Figure 3B